Christopher Ogden insider trades: CytomX Therapeutics (CTMX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | CTMX | ↓ Sell | 1,624 | $3.05 | $5K | Direct | Jun 17, 2026 (2d) |
| Jun 16, 2025 | CTMX | ↓ Sell | 12,255 | $2.72 | $33K | Direct | Jun 17, 2025 (1d) |
| Mar 18, 2025 | CTMX | ↓ Sell | 8,551 | $0.60 | $5K | Direct | Mar 20, 2025 (2d) |
| Aug 20, 2024 | CTMX | ↓ Sell | 1,984 | $1.23 | $2K | Direct | Aug 22, 2024 (2d) |
| Mar 19, 2024 | CTMX | ↓ Sell | 2,971 | $2.09 | $6K | Direct | Mar 21, 2024 (2d) |
| Dec 20, 2023 | CTMX | ↓ Sell | 1,990 | $1.38 | $3K | Direct | Dec 22, 2023 (2d) |
| Mar 16, 2023 | CTMX | ↓ Sell | 516 | $1.98 | $1K | Direct | Mar 20, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christopher Ogden's insider trades
Christopher Ogden is Chief Financial Officer at CytomX Therapeutics (CTMX). Since Mar 16, 2023, Christopher has reported no open-market purchases and 7 sales worth $56K on SEC Form 4. In the last 12 months: 1 sale ($5K).
Their filings also include grants and awards (7 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CTMX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.